The use of a rapid ELISPOT assay to analyze peptide-specific immune responses in carcinoma patients to peptide vs. recombinant poxvirus vaccines

Cancer Immunology Immunotherapy

Volumn 49, Issue 10, 2000, Pages 517-529

  Arlen, Philip ^a   Tsang, Kwong Yok ^a   Marshall, John L ^b   Chen, Alice ^a   Steinberg, Seth M ^a   Poole, Diane ^a   Hand, Patricia Horan ^a   Schlom, Jeffrey ^a   Hamilton, J Michael ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b GEORGETOWN UNIVERSITY   (United States)

Author keywords

Avipox CEA; Cancer vaccine; Carcinoma; CEA peptide; ELISPOT assay; Immune responses

Indexed keywords

CANCER VACCINE; CARCINOEMBRYONIC ANTIGEN; GAMMA INTERFERON; HLA A2 ANTIGEN; IMMUNOGLOBULIN G; PEPTIDE; RECOMBINANT VACCINE; VIRUS VACCINE;

ANTIGEN EXPRESSION; ARTICLE; CANCER PATIENT; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CYTOKINE PRODUCTION; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; HUMAN CELL; IMMUNE RESPONSE; PRIORITY JOURNAL; T LYMPHOCYTE; VACCINATION;

EID: 0033660909     PISSN: 03407004     EISSN: None     Source Type: Journal    
DOI: 10.1007/s002620000145     Document Type: Article

References (76)

1. Mutant ras epitopes as targets for cancer vaccines
2. Dendritic cells pulsed with CEA peptide induce CEA-specific CTL with restricted TCR repertoire
3. Phenotypic analysis of antigen-specific T lymphocytes
4. Enumeration of IFN-gamma-producing cells by flow cytometry. Comparison with fluorescence microscopy
5. Cell-mediated immune responses to MUC-1 fusion protein coupled to mannan
6. The minimum peptide epitope from the influenza virus matrix protein. Extra and intracellular loading of HLA-A2
7. A one-stage procedure for isolation of granulocytes and lymphocytes from human blood. General sedimentation properties of white blood cells in a 1g gravity field
8. Coordinate regulation of complex T-cell populations responding to bacterial infection
9. + T cells during the primary immune response to Epstein-Barr virus in vivo
10. Cytokine dysregulation in invasive cervical carcinoma and other human neoplasias: Time to consider the Th1/Th2 paradigm
11. A carcinoembryonic antigen polynucleotide vaccine for human clinical use
12. Human autoantibodies to carcinoembryonic antigen (CEA) induced by a vaccinia-CEA vaccine
13. Precursor frequency analysis of human cytolytic T lymphocytes directed against autologous melanoma cells
14. Mice transgenic for the human carcinoembryonic antigen gene maintain its spatiotemporal expression patterns
15. The labyrinthine ways of cancer immunotherapy - T cell, tumor cell encounter: 'How do I lose thee? Let me count the ways'
16. Role of cytokines in rheumatoid arthritis
17. Loss of T-cell receptor zeta chain and p561ck in T cells infiltrating human renal cell carcinoma
18. Identification of an immunodominant peptide of HER-2/neu protooncogene recognized by ovarian tumor-specific cytotoxic T lymphocyte lines
19. Enhanced expression of HLA-A,B,C and inducibility of TAP-2 and HLA-A,B,C, by interferon-gamma in a multidrug-resistant small cell lung cancer line
20. Immunization with CEA agonist epitope pulsed FLT3L expanded dendritic cells for human tumor immunotherapy
21. Immune response to the carcinoembryonic antigen in patients treated with an antiidiotype antibody vaccine
22. + T lymphocytes, generated by mutant p21-ras (12VAL) peptide vaccination of a patient, recognize 12VAL-dependent nested epitopes present within the vaccine peptide and kill autologous tumour cells carrying this mutation
23. Generation of hybrid genes and proteins by vaccinia virus-mediated recombination: Application to human immunodeficiency virus type 1 env
24. Quantitative analysis of CEA expression in colorectal adenocarcinoma and serum: Lack of correlation
25. A new membrane permeabilization method for the detection of intracellular antigens by flow cytometry
26. Phase I study of recombinant vaccinia virus (rV) that expresses human carcinoembryonic antigen (CEA) in adult patients with adenocarcinomas
27. Diversified prime and boost protocols using recombinant vaccinia virus and recombinant non-replicating avian pox virus to enhance T-cell immunity and antitumor responses
28. Mutations in the alpha 2 helix of HLA-A2 affect presentation but do not inhibit binding of influenza virus matrix peptide
29. In vitro induction of human cytotoxic T lymphocyte responses against peptides of mutant and wild-type p53
30. An evaluation of the potential to use tumor-associated antigens as targets for antitumor T cell therapy using transgenic mice expressing a retroviral tumor antigen in normal lymphoid tissues
31. Cytokine production by peripheral blood monocytes/macrophages in multiple sclerosis patients
32. Cytotoxic T cells from ovarian malignant tumors can recognize polymorphic epithelial mucin core peptides
33. The use of combination vaccinia vaccines and dual-gene vaccinia vaccines to enhance antigen-specific T-cell immunity via T-cell costimulation
34. Anti-tumor activity and immune responses induced by a recombinant vaccinia-carcinoembryonic antigen (CEA) vaccine
35. Antibody and T cell responses of patients with adenocarcinoma immunized with mannan-MUC1 fusion protein
36. Induction of protective host immunity to carcinoembryonic antigen (CEA), a self-antigen in CEA transgenic mice, by immunizing with a recombinant vaccinia-CEA virus
37. Preliminary results of ALVAC-CEA-B7 phase I vaccine trial in patients with metastatic CEA-expressing tumors
38. Characterization of IgG and IgM antibodies induced in melanoma peptides by immunization with purified GM2 ganglioside
39. Phase I study in cancer patients of a replication-defective avipox recombinant vaccine that expresses human carcinoembryonic antigen
40. Phase I/II trial of rV-CEA (V) and ALVAC-CEA (A) in patients with advanced CEA-bearing tumors
41. Phase I study in cancer patients of a diversified prime and boost immunization protocol using recombinant vaccinia virus and recombinant nonreplicating avian pox virus to elicit an anti-carcinoembryonic antigen immune response
42. Enumeration and characterization of memory cells in the TH compartment
43. Anti-tyrosinase antibodies in malignant melanoma
44. CEA tissue staining in colorectal cancer patients. A way to improve the usefulness of serial serum CEA evaluation
45. A phase I study of active immunotherapy with carcinoembryonic antigen peptide (CAP-1)-pulsed, autologous human cultured dendritic cells in patients with metastatic malignancies expressing carcinoembryonic antigen
46. Definition by monoclonal antibodies of a repertoire of epitopes on carcinoembryonic antigen differentially expressed in human colon carcinomas versus normal adult tissues
47. Decreased expression of the signal-transducing zeta chains in tumor-infiltrating T cells and NK cells of patients with colorectal carcinoma
48. HLA-A2601-restricted CTLs recognize a peptide antigen expressed on squamous cell carcinoma
49. Improved induction of melanoma-reactive CTL with peptides from the melanoma antigen gp100 modified at HLA-A*0201-binding residues
50. Immunization of patients with melanoma peptide vaccines: Immunologic assessment using the ELISPOT assay
51. Sequence analysis of carcinoembryonic antigen: Identification of glycosylation sites and homology with the immunoglobulin supergene family
52. + T cells in peripheral blood of colorectal cancer patients and involvement in cancer establishment and progression
53. Occasional memory cytotoxic T-cell responses of patients with human papillomavirus type 16-positive cervical lesions against a human leukocyte antigen-A*0201-restricted E7-encoded epitope
54. Recombinant anti-cancer vaccines
55. Definition of the expression of the human carcinoembryonic antigen and non-specific cross-reacting antigen in human breast and lung carcinomas
56. Lymphocyte production by human T cells in disease states
57. p53 as a target for cancer vaccines: Recombinant canarypox virus vectors expressing p53 protect mice against lethal tumor cell challenge
58. Agonist peptide from a cytotoxic T lymphocyte epitope of human carcinoembryonic antigen stimulates production of Tc1-type cytokines and increases tyrosine phosphorylation more efficiently than cognate antigen
59. Pharmacological administration of granulocyte/macrophage-colony-stimulating factor is of significant importance for the induction of a strong humoral and cellular response in patients immunized with recombinant carcinoembryonic antigen
60. Impaired production of Th1 cytokines and increased frequency of Th2 subsets in PBMC from advanced cancer patients
61. + T lymphocytes specific for HLA class I-binding peptide epitopes derived from influenza proteins in the blood of healthy donors and melanoma patients
62. Carcinoembryonic antigen as a vaccine target
63. Carcinoembryonic antigen in breast cancer patients: Serum levels and disease progress
64. NK susceptibility varies inversely with target cell class I HLA antigen expression
65. Limiting dilution assays for the determination of immunocompetent cell frequencies. 1. Data analysis
66. Carcinoembryonic antigen gene family: Molecular biology and clinical perspectives
67. Expression of transgenic carcinoembryonic antigen (CEA) in tumor-prone mice: An animal model for CEA-directed tumor immunotherapy
68. Induction of human cytotoxic T-cell lines directed against point-mutated p21 ras-derived synthetic peptides
69. Generation of human cytotoxic T cells specific for human carcinoembryonic antigen epitopes from patients immunized with recombinant vaccinia-CEA vaccine
70. Phenotypic stability of a cytotoxic T cell line directed against an immunodominant epitope of human carcinoembryonic antigen
71. Enumeration of IFN-gamma-producing human lymphocytes by spot-ELISA: A method to detect lymphokine-producing lymphocytes at the single-cell level
72. Carcinoembryonic antigen as a monitor of successful surgical resection in 130 patients with carcinoma of the lung
73. Active immunotherapy of cancer with a nonreplicating recombinant fowlpox virus encoding a model tumor-associated antigen
74. Induction of primary, human antigen-specific cytotoxic T lymphocytes in vitro using dendritic cells pulsed with peptides
75. Induction of human cytotoxic T lymphocytes specific for prostate-specific antigen
76. Identification of an enhancer agonist CTL peptide from human carcinoembryonic antigen